223 related articles for article (PubMed ID: 22693251)
1. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
3. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.
Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123
[TBL] [Abstract][Full Text] [Related]
4. Cancer-Associated Point Mutations in the
Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Qian X; Durkin ME; Wang D; Tripathi BK; Olson L; Yang XY; Vass WC; Popescu NC; Lowy DR
Cancer Res; 2012 Nov; 72(22):5900-11. PubMed ID: 23010077
[TBL] [Abstract][Full Text] [Related]
6. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
7. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
8. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
9. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
[TBL] [Abstract][Full Text] [Related]
10. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
11. GAP-independent functions of DLC1 in metastasis.
Barras D; Widmann C
Cancer Metastasis Rev; 2014 Mar; 33(1):87-100. PubMed ID: 24338004
[TBL] [Abstract][Full Text] [Related]
12. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
14. Fluctuation of ROS regulates proliferation and mediates inhibition of migration by reducing the interaction between DLC1 and CAV-1 in breast cancer cells.
Yang B; Zhu W; Zheng Z; Chai R; Ji S; Ren G; Liu T; Liu Z; Song T; Li F; Liu S; Li G
In Vitro Cell Dev Biol Anim; 2017 Apr; 53(4):354-362. PubMed ID: 28130753
[TBL] [Abstract][Full Text] [Related]
15. A tumor suppressor DLC1: The functions and signal pathways.
Zhang Y; Li G
J Cell Physiol; 2020 Jun; 235(6):4999-5007. PubMed ID: 31773748
[TBL] [Abstract][Full Text] [Related]
16. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
Chan LK; Ko FC; Sze KM; Ng IO; Yam JW
PLoS One; 2011; 6(9):e25547. PubMed ID: 21966542
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
18. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
